Furthermore, CYCLON was identified to be an autonomous tumour growth driver that cooperates with MYC to drive aggressive lymphoma growth in vivo thus further rationalizing the value of therapeutically targeting this factor in lymphoid malignancies. Here, CCDC86 is linked to lymphoma.